Agenda
Keynote Sessions
Digital Transformation
Automation & Robotics
AI
Data Strategy
Scientific Innovation
Interoperability & Connectivity
Lab Operations
08:55
Moderator’s Introduction
Keynote Sessions
08:55 - 09:00 ET
09:00
The Digital Transformation Journey – are we there yet?
Keynote Sessions
09:00 - 09:15 ET
09:15
Cloud as Catalyst: Laying the Data Foundations for Future-Ready Labs
Keynote Sessions
09:15 - 09:30 ET
  • Labs exist in the physical world, but the ability to integrate lab operations is in the cloud. Lee will be giving an overview of how AWS is working with life science companies and scientific software makers, discussing why data foundations are important for automation and AI, and sharing success stories of new digital laboratory operations.
09:30
Digital Lab Transformation and the Workforce of the Future
Keynote Sessions
09:30 - 09:45 ET
09:45
Panel Discussion
Keynote Sessions
09:45 - 10:00 ET
10:00
Moderator’s Introduction
Keynote Sessions
10:00 - 10:05 ET
Michael Shanler, VP Distinguished Analyst, Gartner
10:05
Collaboration as the key to delivering the benefits of the connected lab ecosystem
Keynote Sessions
10:05 - 10:20 ET

Thermo Fisher Scientific

10:20
Convergence: Where Data and DNA Meet
Keynote Sessions
10:20 - 10:35 ET
10:35
Breakthrough Research and Early Development Tools to Support Diagnostics
Keynote Sessions
10:35 - 10:50 ET
10:50
Panel Discussion
Keynote Sessions
10:50 - 11:05 ET
Michael Shanler, VP Distinguished Analyst, Gartner
11:05
Coffee Break and Exhibition
11:05 - 11:45 ET
11:45
Unlocking the Power of Data: A Journey of Digital Transformation in Development Sciences
Digital Transformation
11:45 - 12:10 ET
Mohit Agnihotri, Senior Director, Development Sciences Data & Digital Strategy, AbbVie
Mira Hinman, Director, Scientific Architecture, Development Sciences Digital Transformation, AbbVie

Development Sciences is undertaking a business transformation, implementing our vision of a digitally integrated organization that leverages data as an asset. We are actively applying advancements in digital technologies to everyday work processes. This session will explore how the transformation program is structured, operating methodology & dive into the impacts of Digital Transformation in the lab. Using example case studies from the CMC & Biological Sciences functions we will share contrasting insights into the challenges, success stories and lessons learnt along the way.

Infrastructure of the Future
Automation & Robotics
11:45 - 12:00 ET

Like the term “workflow”, the scope of any “Lab of the Future” will vary widely across organizations. We expect specialized talent, technology, and “workflows” are unique for any project. This brief presentation will focus on the common challenges and generalized infrastructure tools and tactics to be successful in the “Lab of YOUR Future” project on your horizon. Having the correct infrastructure to build and operate your lab will make the difference between a (very) expensive lab used to generate your social media buzz or a functioning lab which has resulted in scaling your output of medicines.

Keynote Address: Emerging Opportunities to Accelerate Drug Discovery
Keynote Sessions
11:45 - 12:00 ET
1) New paradigms for target discovery
2) Digital-twins for therapeutic margin
3) Generative AI for molecular design
12:00
Research Automation Technologies at Amgen
Automation & Robotics
12:00 - 12:10 ET
Biologics AI Moonshot: Building the Next Generation Digital Biologics Platform
AI
12:00 - 12:10 ET
Yves Fomekong Nanfack, Head of End to End AI Foundations, Large Molecules Research Platform, Sanofi
Yves will discuss methods for accelerating and improving success probability of large molecule discovery. Methods featured will include AI-guided hit discovery, industrialization of AI/ML models for biologics design and democratization of experimental and in silico data access. Yves will also highlight the importance of improving researcher efficiency and experience.
• Acceleration of large molecule discovery time and improve probability of success.
• Industrialization of AI/ML models for biologics design and discovery
• Democratization of experimental and in silico data access and enabling AI guided hit discovery
• Improving researcher efficiency and experience through a streamlined process
12:10
Fairification of Data and Process: A Unified Platform Approach with Workflow Orchestration & Data Contextualization
Digital Transformation
12:10 - 12:25 ET
Connecting the lab ecosystem – driving better, insightful and more efficient decisions
Automation & Robotics
12:10 - 12:25 ET
The Lab AI Revolution: Unleashing the Power of AI and Data to Accelerate Research and Discovery Rob Brown, Senior Director of Product Marketing, Sapio Sciences
AI
12:10 - 12:25 ET

• Leveraging the power of AI in a next generation lab informatics platform
• An AI digital assistant to create experiment content and perform advanced scientific search
• Powering adoption and productivity with AI support assistants and code generation
• Unifying and contextualizing research data to build & apply AI/ML models

12:25
Panel Discussion and Q&A
Digital Transformation
12:25 - 12:40 ET
Mohit Agnihotri, Senior Director, Development Sciences Data & Digital Strategy, AbbVie
Mira Hinman, Director, Scientific Architecture, Development Sciences Digital Transformation, AbbVie
Panel Discussion and Q&A
Automation & Robotics
12:25 - 12:40 ET
Panel Discussion and Q&A
AI
12:25 - 12:40 ET
Yves Fomekong Nanfack, Head of End to End AI Foundations, Large Molecules Research Platform, Sanofi
12:40
Lunch & Exhibition
12:40 - 13:40 ET
13:40
Knowledge Retention & Fostering Engagement
Digital Transformation
13:40 - 13:55 ET
Jennifer Perkins, Data Sciences Project Manager, Pfizer
Boost participation with a platform to speak
Attract and retain members through efficiency and value
Engagement is tied to community management
Provide development opportunities
Automated Reaction Development to Enable the Efficient Synthesis of Diverse and Complex Small Molecules
Automation & Robotics
13:40 - 13:55 ET

Automated synthesis, traditionally limited to broad reaction conditions yielding combinatorial compounds, requires tailoring specific conditions to individual reactants to produce diverse and discrete small molecules, akin to a chemist’s benchwork approach.
Tailored reaction conditions lead to increased confidence in reaction success, higher yields, and the incorporation of more complex building blocks in the synthesis process.
In this work, we outline our approach to reaction development, defining substrate scope and automating reaction processes for a chemistry platform, thereby enabling the synthesis of lead-like small molecules with higher recoveries and achieving broader chemical space coverage through automated multistep synthesis

AI at AbbVie: Moonshot, Woodstock, Watergate, Punk Rock
AI
13:40 - 13:55 ET

Choosing a path forward involves balancing a set of different challenges. This brief talk will discuss those challenges and how we at AbbVie have been approaching them for the past 5+ years in the field of AI research and development.
– Do you shoot for the moon by investing in novel molecule generators for drug discovery?
– Do you try and bring everyone together in a “kum ba yah” way to find the path forward? – How do you navigate the murky gray waters between opportunity and obligation – reputation and regulation?
– How do you latch on to the seemingly limitless energy that powers innovation?

13:55
Rethinking the Role of ELNs – Are we making things worse?
Digital Transformation
13:55 - 14:10
Bringing AI/ML Into Regulated Bioanalytical Laboratories
Automation & Robotics
13:55 - 14:10 ET
Exploiting recent computational advances for drug discovery: A view from the industry
AI
13:55 - 14:10 ET

Christolaou Nicolaou, Senior Scientific Director, Digital Small Molecule Lead, Novo Nordisk

14:10
Navigating software changes with confidence: Don’t Fear your Updates!
Automation & Robotics
14:10 - 14:20 ET
Making life-science data AI-ready
AI
14:10 - 14:20

Building an end-to-end data ecosystem to go from data to insights is not trivial. Breaking data silos through seamless data integration, interoperability and provenance is the precursor to driving any successful data initiatives in BioPharma. In this session Dr Abhishek Jha will talk about how Elucidata’s data harmonization engine, Polly is making life-sciences data AI-ready through large scale multi-modal and multi-source data harmonization, high quality data and our differentiated ML-ops services.

14:20
Panel Discussion and Q&A
Digital Transformation
14:20 - 14:35 ET
Jennifer Perkins, Data Sciences Project Manager, Pfizer
Panel Discussion and Q&A
Automation & Robotics
14:20 - 14:35 ET
Panel Discussion and Q&A
AI
14:20 - 14:35 ET
John Overington, Chief Data Officer, Exscientia
14:35
Change Management
Digital Transformation
14:35 - 14:50 ET
Lab of the Future Initiatives at Moderna
Automation & Robotics
14:35 - 14:50 ET

Mohit will speak on Moderna’s Lab of the Future initiative featuring robotics, automation, and integrating these technologies into existing lab processes.

Logica: Disrupting drug discovery
AI
14:35 - 14:50 ET
Alison Jones, Senior Director, Chemistry, Charles River Laboratories
Leveraging AI in drug discovery
Reducing the risk of failure
Shortening the timelines
14:50
Revolutionaizing Chromatography Data Management: A Data-Driven Approach to Digital Transformation
Digital Transformation
14:50 - 15:00 ET
Pankaj Aggrawal, Associate Principal Scientist, Merck

Our data science team led a initiative to transform chromatography data management in laboratory operations, embracing a data-driven approach. This innovation has unlocked the full potential of chromatography data for improved pharmaceutical research and development. Our strategies encompass robust data collection, integration, advanced analytics, predictive modeling, and fostering collaboration. Moreover, we recognize the significance of managing cultural change in the adoption of new tools to successfully navigate the digital transformation journey. As a result, our organization has achieved enhanced efficiency, improved quality, proactive decision-making, and accelerated innovation. This presentation will share our experiences and adopted approaches, inspiring others to embark on their own digital transformation journeys.

From Conception to Implementation, A Fully Automated Compound Management Lab
Automation & Robotics
14:50 - 15:00 ET

– Conception: What goal are we trying to achieve with our software and hardware?
– Conception: What automation and software do we need to purchase to enable our new workflows?
– Implementation: How we connected our new automation and existing software and the pro’s/con’s of how we did it
– Conclusion: What we ultimately achieved and what we would do differently next time

AI for therapeutic target and indication prioritization
AI
14:50 - 15:05 ET
o Data driven target and indication prioritization to improve clinical trial success
o Multi-modal target discovery engine – example of Parkinson’s disease
o Indication expansion and drug repurposing
15:00
Lab Ecosystem Integration is Critical to Digital Transformation
Digital Transformation
15:00 - 15:15 ET
  • Platform integration vs point to point integration
  • The role of GenAI in platform integration
  • Transforming the nature of traditional automation to add a new interactive model
Lab Data Automation for Cell Culture Development and Other Challenging Applications
Automation & Robotics
15:00 - 15:15 ET
  • How FAIR data principles require implementing data automation alongside lab workflows
  • Approaches to integrating data automation into the existing R&D IT ecosystem and the importance of bi-directional dataflow
  • Lessons learned from building complex instrument connections
  • Where is lab data automation heading: Our outlook
Specializing GPTs for The Drug Development Life Cycle
AI
15:00 - 15:15 ET
  • Challenges and considerations for AI deployments
  • Accelerating medical writing with generative AI
  • GPTs beyond content creation – AI and its role in clinical outcomes prediction
  • Automating Systematic literature review
15:15
Panel Discussion and Q&A
Digital Transformation
15:15 - 15:30 ET
Pankaj Aggrawal, Associate Principal Scientist, Merck
Panel Discussion and Q&A
Automation & Robotics
15:15 - 15:30 ET
Panel Discussion and Q&A
AI
15:15 - 15:30 ET
John Overington, Chief Data Officer, Exscientia
Alison Jones, Senior Director, Chemistry, Charles River Laboratories
15:30
Tea Break and Exhibition
15:30 - 16:10 ET
16:10
Enabling Tools for CMC Digital Transformation
Digital Transformation
16:10 - 16:25 ET
Douglas Scheesley, Director of Continous Improvement Program Management, GSK
Global sample tracking and workflow management in drug discovery – does it matter?
Automation & Robotics
16:10 - 16:25 ET

1. User-experience in tracking and recognition of multi-player analytical workflows

2. Objective measures of turnover times, project-relevant challenges, and workflow bottlenecks

AI Assistants for Biological Discovery: Working smarter not Harder in Drug Discovery
AI
16:10 - 16:25 ET
Low probability of success has historically been the key challenge in drug discovery. A deluge of data exists today to potentially inform us about biological and chemical properties related to successful medicines but making sense of this data remains a challenge.
Patrick will outline how automated and autonomous AI assistants are making a difference in drug discovery today to enable us to derive causal insights from large-scale datasets faster and with higher precision.
16:25
Enabling scientists to drive innovation: digital transformation as a key foundation for a successful journey
Digital Transformation
16:25 - 16:50 ET

Challenges and barriers that can hinder organizations innovation and growth potential.
The role of a LIMS in supporting the laboratory’s digital transformation journey.
Examples and best practices of how digital transformation can enable organizations not only to achieve greater efficiency and productivity but make an impact in their fields.

Fully-automated Multi-Modal Transformer-Driven Lab: One Year in Review
Automation & Robotics
16:25 - 16:35 ET
Machine learning for target discovery
AI
16:25 - 16:40 ET
This presentation will introduce the audience to the field of antigen discovery using reverse vaccinology for subunit vaccine design.
There will be a detailed description of the first application of machine learning to reverse vaccinology.
We will conclude with a template for applying these techniques to target identification in polygenic diseases with a full discussion of the obstacles and solution space in this domain.
16:35
Solving the new bottlenecks in therapeutics R&D with automation and artificial intelligence
Automation & Robotics
16:35 - 16:50
Harnessing Advanced Experimental Design to Optimize AAV Production
Automation & Robotics
16:35 - 16:50 ET
  • How implementation of a novel Design of Experiments platform has allowed for the creation of more complex experimental designs.
  • Increasing efficiency and reducing workload for scientists through eradicating the need for program automation instructions into Hamilton STARlet and SPT dragonfly dispensers
  • Results to date and next steps
16:50
Panel Discussion and Q&A
Digital Transformation
16:50 - 17:05 ET
Douglas Scheesley, Director of Continous Improvement Program Management, GSK
Panel Discussion and Q&A
Automation & Robotics
16:50 - 17:05 ET
Panel Discussion and Q&A
AI
16:50 - 17:05 ET
17:05
Live Labs Session – How do we support the new science?
Keynote Sessions
17:05 - 17:50 ET

Live Lab sessions are interactive group discussions which tackle the bigger questions of the day in an open forum to brainstorm ideas and discuss the roadblocks to break-through innovation. They take the format of moderated standing discussions. The objective is to share views and experiences to stimulate new ways of thinking about common objectives. They are moderated and scheduled for 45 minutes

How do we support the new science?

Live Labs Session – Lab of the Future – why aren’t we there yet?
Keynote Sessions
17:05 - 17:50 ET
Michael Shanler, VP Distinguished Analyst, Gartner

Live Lab sessions are interactive group discussions which tackle the bigger questions of the day in an open forum to brainstorm ideas and discuss the roadblocks to break-through innovation. They take the format of moderated standing discussions. The objective is to share views and experiences to stimulate new ways of thinking about common objectives. They are moderated and scheduled for 45 minutes

Lab of the Future – why aren’t we there yet?

Live Labs Session – How do we deliver responsible AI?
Keynote Sessions
17:05 - 17:50 ET

Live Lab sessions are interactive group discussions which tackle the bigger questions of the day in an open forum to brainstorm ideas and discuss the roadblocks to break-through innovation. They take the format of moderated standing discussions. The objective is to share views and experiences to stimulate new ways of thinking about common objectives.

17:50
Drinks Reception
Keynote Sessions
17:50 ET
09:00
Moderator’s Introduction
Keynote Sessions
09:00 - 09:05 ET
Michael Shanler, VP Distinguished Analyst, Gartner
09:05
Unlocking the Power of the Proteome in New Medicines Development
Keynote Sessions
09:05 - 09:20 ET
09:20
Elevating Innovation Through Co-Creative Partnerships
Keynote Sessions
09:20 - 09:35 ET
09:35
Empowering the Digital Laboratory: Principles, Blueprints, and Real-World Examples
Keynote Sessions
09:35 - 09:50 ET

In the rapidly evolving landscape of scientific research, laboratories are embracing digitalization to enhance workflows, drive automation, and leverage data as a valuable asset with the support of artificial intelligence.
In this keynote presentation, we will delve into the key principles and blueprints that underpin successful digitalization efforts, including data integration and harmonization, process automation, interoperability, and the utilization of artificial intelligence. Furthermore, we will showcase real-world examples that demonstrate the value and impact of digitalization on the journey towards the digital lab.

09:50
Panel discussion & Q&A
Keynote Sessions
09:50 - 10:15 ET
Michael Shanler, VP Distinguished Analyst, Gartner
10:15
Digital Transformation and Drug Discovery
Keynote Sessions
10:15 - 10:30 ET
10:30
Empowering the Future of Collaborative, Digital Drug Discovery – From Small to Large Molecules
Keynote Sessions
10:30 - 10:45 ET
10:45
LLMs and Liquid Handlers and GPTs, Oh My! Lab Automation in the Age of GenAI
Keynote Sessions
10:45 - 11:00 ET
11:00
Panel Discussion & Q&A
Keynote Sessions
11:00 - 11:25 ET
Michael Shanler, VP Distinguished Analyst, Gartner
Jessica Hilton, Senior Director, Resource Planning and Management Lead, Pfizer
11:25
Coffee & Exhibition
11:25 - 12:15 ET
12:15
Is Informatics Heaven Found in the Cloud?
Data Strategy
12:15 - 12.30 ET

SaaS platforms are popular, especially with IT departments. Is it really a dream come true win-win for everyone? We’ll discuss some of the tradeoffs that you might be seeing when applications move to the cloud.

A New Era – Leveraging XR, Voice Assistance and Automation to Benefit Research Within the BioTech Industry
Automation & Robotics
12:15 - 12:30 ET
The Lab of the Future Program at Sanofi
Lab Operations
12:15 - 12:30 ET

The Lab of the Future Program at Sanofi

12:30
Lessons from Laboratory Raw Data Movement
Data Strategy
12:30 - 12:40 ET

Christopher will present lessons learned from Laboratory Raw Data Movement from wet labs to cloud storage and the challenges associated with acquiring, transferring, accessing, and visualizing data in a startup environment.

12:40
Maximizing the Value of the Data Captured by Your Data Strategy Project
Data Strategy
12:40 - 12:55 ET

So, you moved some data to the Cloud, what’s next? Getting your data to the cloud is a step in a digital transformation project. We’ll discuss how to avoid pitfalls and ensure that your project unlocks value for your organization.

Realizing analytical data analysis productivity gains in the laboratory with cloud-enabled workflow automation, tools, and technologies
Automation & Robotics
12:40 - 12:55 ET
  1. A review of how our planned software structure can enable automation, efficiency, and increase productivity.
  2. An exploration of how we are building our software tools to enhance seamless adoption, use and flexibility.
  3. A look at how we are designing our software ecosystem to support data agility, utility and leverage it for AI/ML steps to come
An Informatics Strategy Blueprint for Digitizing Diagnostic Testing
Lab Operations
12:40 - 12:55 ET
  • Outlining the steps carried out for successful implementation of a fully digital workflow within diagnostic testing processes – taking into consideration lab informatics strategy and implementation of best practices.
  • Methods for enhancing efficiency, accuracy and scalability in diagnostic testing operations through digitalization. 
12:55
Panel Discussion and Q&A
Data Strategy
12:55 - 13:10 ET
Panel Discussion and Q&A
Automation & Robotics
12:55 - 13:10 ET
Lisa Shipley, Founder, Shipley Pharma Insights
Panel Discussion and Q&A
Lab Operations
12:55 - 13:10 ET
13:10
Lunch & Exhibition
13:10 - 14:10 ET
14:10
Pistoia Alliance Lab2030: A cross-pharma collaborative to accelerate the adoption of emerging technology
Data Strategy
14:10 - 14:25 ET
From data as a by-product to data as a product: a paradigm shift in Pharma R&D
Interoperability & Connectivity
14:10 - 14:25 ET
  • Apply product mindset to data management and ownership
  • Implement FAIR data principles to improve interoperability and connectivity of data
  • Drive business value from data via visualization and knowledge
Innovative resourcing solutions to accelerate the development of novel therapies: A hybrid approach including infrastructure, operations, and expertise
Lab Operations
14:10 - 14:25 ET
  • Challenges of traditional lab infrastructure
  • Modular lab framework that enables multifunctional, enterprise-quality research environments to be configured and ready for use within weeks
  • Unique model that integrates operational support and expert guidance into the delivery of lab spaces across research and development, in vivo, and drug manufacturing environments
  • Case studies showing how our modular lab framework, operational support and expertise have allowed Members to pivot quickly
14:25
Cloud Migration – a disruptive process
Data Strategy
14:25 - 14:35 ET
Why are we doing it?
Understand the current system vs the expected system.
Impact of the migration on each components involved.
Define strategies & focus.
Challenge we encountered on our way and how we overcame them
Allotrope Foundation: Delivering a Standards Based Framework that Enables the Lab of the Future
Interoperability & Connectivity
14:25 - 14:35 ET

As one of the founding board members of Allotrope Foundation, Joseph will highlight the power of the framework, especially Allotrope Simple Models (ASM)

1. Evolution of Allotrope Foundation
2. Components of the Framework and how they enable frictionless data sharing (and AI/ML!)
3. Examples

Roche Global Procurement Insights & Solutions – An investment in the future of procurement
Lab Operations
14:25 - 14:35 ET

The next evolutionary step in procurement. How do we evolve from a reactive procurement organization to a proactive problem solving function?
To move towards a proactive and customer centric organization, we added new capabilities to understand stakeholder challenges and tackle them by bringing external innovation

14:35
The Reproducible Future of Computational Science
Interoperability & Connectivity
14:35 - 14:50 ET
  • Computational Science has never been more important, or more constrained
  • Huge array of tools to use & connect burden Computational Scientists and slow progress
  • However, Biotech & Pharma teams that adopt FAIRR* analytics can realize huge potential

*Findable, Accessible, Interoperable, Reusable and Reproducible

A Strategy for Delivering Digital Transformation of CMC
Lab Operations
14:35 - 14:50 ET

Overview of our digital CMC vision and Quality be Digital Design Framework for medicines development and manufacturing
Predictive toolbox development for crystallisation (CCS) and drug product (MCS+)
Building the data fabric to support product and process development
Data factories and automated workflows to accelerate development
Challenges & opportunities for industrial digital technologies in CMC

14:50
Panel Discussion and Q&A
Data Strategy
14:50 - 15:05 ET
Lisa Shipley, Founder, Shipley Pharma Insights
Panel Discussion and Q&A
Interoperability & Connectivity
14:50 - 15:05 ET
Panel Discussion and Q&A
Lab Operations
14:50 - 15:05
Anna Greenswag, Director Lab and Infrastructure Continuous Improvement, Ginkgo Bioworks
15:05
Launching Avidity’s Digital Journey: Establishing and Expanding our Digital Landscape
Data Strategy
15:05 - 15:20 ET
Cindy Novak, Associate Director, R&D Systems, Avidity Biosciences

Cindy will discuss how Avidity launched their digital journey and gained leadership and user acceptance. She will also highlight the challenges and successes along the way, as well as the next steps and lessons learnt.

RNA Therapeutics in the Digital Age: A Visually Interactive and Digitally Integrated Ecosystem for the Rapid Synthesis of Chemically Modified Oligonucleotides
Scientific Innovation
15:05 - 15:20 ET
A digital platform enabling the web-based design and rapid synthesis of highly chemically modified RNA molecules will be described.
The platform features a visually intuitive and fully interactive interface to design, edit, view, and export RNA sequences suitable to be read by high-throughput laboratory synthesizer machines.
An API integration to an internal database of chemically modified nucleoside base units along with other structural elements allows for representation of the complete atomic structure of highly complex RNA therapeutic molecules.
Visual meaning for each major structural unit is encoded through a controlled list of shape and color specifications, allowing for universal understanding and extensibility to new chemical design features.
Scaling Digital Lab Operations
Lab Operations
15:05 - 15:20 ET
  • Moderna Tx
    • Scaling of operations from 500 to 5,000 people in 3 years
    • Equipment power utilization strategy and monitoring
    • Sample management – digitalization
  • Lab Ops Unite
    • Vision and goals, needs to be addressed
    • Creating lab ops best practices, leveraging expertise
15:20
Development of a LIMS Framework that Drives Innovation in Early Research
Data Strategy
15:20 - 15:30 ET
Using Next-Gen CRISPR, Multiplex Technology to Identify, Target and Excise Viruses with Greater Precision
Scientific Innovation
15:20 - 15:35 ET

• Evolving Computational methods for multiplex viral targeting with CRISPR
• Improved bioinformatics elucidates highly conserved targets with low similarly to the human genome
• Effective screening identifies highly active pairs of target sites driving excision of virus
• Advanced model systems allows testing to improve efficacy and verify specificity

Eyes on the Prize: Building a Data Centric Ecosystem and Culture
Lab Operations
15:20 - 15:30 ET
Prioritizing Data in Design Thinking
Meeting users where they are
Aligning Architecture with Reality
Practical examples of data-centric projects: progress, challenges, and the current status of our journey
15:30
Optimizing Data Management for Histology and Cellular Imaging Research: Challenges and Opportunities
Data Strategy
15:30 - 15:45 ET

Histology and cellular imaging data play a crucial role in advancing the diagnosis and understanding of complex disease traits. Establishing a comprehensive data strategy for these datasets is essential to ensure research teams can efficiently access, analyze, and utilize them. This presentation will emphasize the significance of developing a data strategy for histology and cellular imaging data, including the best practices for data collection, storage, sharing, and analysis, and how Novo Nordisk is implementing them. Additionally, the presentation will explore the challenges and opportunities involved in developing a data strategy in this field, such as data standardization, privacy concerns, and emerging technologies.

Back to Basics: Asset Loss Prevention
Lab Operations
15:30 - 15:45 ET
  • Connected data alone will not prevent asset loss, but Monitoring-as-a-Service can
  • The right EMS should act as an extension of your team, provide knowledge, and have the right experience to help you
  • Having expert support helps safeguard your lab and prevent loss
15:45
Panel Discussion and Q&A
Data Strategy
15:45 - 16:00 ET
Cindy Novak, Associate Director, R&D Systems, Avidity Biosciences
Panel Discussion and Q&A
Scientific Innovation
15:45 - 16:00 ET
Panel Discussion and Q&A
Lab Operations
15:45 - 16:00 ET